Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05133778
Other study ID # Actiful2
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date November 1, 2021
Est. completion date December 31, 2022

Study information

Verified date October 2021
Source Maastricht University
Contact Freddy Troost, Dr.
Phone +31(0)43 3884296
Email f.troost@maastrichtuniversity.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of the present study is to investigate the effect of 12-week long daily administration of a sweet orange and pomegranate extract on exercise capacity in healthy adults.


Description:

Background of the study: Polyphenols have been studied for their protective effect against the development of ROS-related diseases like cancers, cardiovascular diseases, diabetes, osteoporosis, and neurodegenerative diseases. The combined supplementation of pomegranate and sweet orange polyphenols could be an effective strategy to improve exercise performance, due to their antioxidant character and ability to stimulate NO production, to stimulate mitochondrial biogenesis and to accelerate muscle repair and decrease muscle tissue damage. The study aims to assess the effect of a combined supplementation of pomegranate and sweet orange extract on exercise capacity, physical activity, muscle strength and quality of life in healthy adults. Objective of the study: The aim of the present study is to investigate the effect of 12-week long daily administration of a sweet orange and pomegranate extract on exercise capacity in healthy adults (40 - 65 y). Study design: Randomized, double-blind, placebo-controlled parallel trial Study population: Healthy, overweight, sedentary adults between 40 and 65 years old. Intervention: 12-week supplementation with 650 mg sweet orange and pomegranate extract (2 capsules per day) compared to placebo (760 mg maltodextrin). Primary outcome of the study: Change in aerobic capacity (VO2max), assessed with an Ekblom-Bak submaximal cycling test. Secondary study parameters/outcome of the study: - Daily physical activity as determined by accelerometer - Dietary intake as measured by a 3-day food record - Handgrip strength - Muscle cell proliferation and differentiation and mitochondrial biogenesis assessed in skeletal muscle biopsies - Quality of Life as measured by the WHO-QOL-100 questionnaire - General health as measured by SF-36 questionnaire - Vitality as measured by the Dutch Vitality Questionnaire (Vita-16) - Cardiometabolic health biomarkers, cortisol, C-reactive protein determined with ELISA - Antioxidative capacity measured with a Trolox equivalent antioxidant capacity (TEAC) assay


Recruitment information / eligibility

Status Recruiting
Enrollment 52
Est. completion date December 31, 2022
Est. primary completion date December 31, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 40 Years to 65 Years
Eligibility Inclusion Criteria: - Healthy male/female (based on medical history provided during a general health questionnaire) - Age between 40 - 65 yrs - Overweight (BMI =25 to =29.9 kg/m2) - Sedentary subjects (Low Level [<600 MET-minutes/week] as assessed by the Physical Activity Questionnaire (IPAQ)) Exclusion Criteria: - Allergy to test product/control or citrus fruits and pomegranate - Medical conditions that might interfere with endpoints or compromise participant safety during testing (e.g. Cardiovascular diseases, cancer, Parkinson's disease, Gastrointestinal diseases or abdominal surgery) to be decided by the principal investigator - Use of medication that might interfere with endpoints (i.e.: ß-blockers, antioxidant, antidepressants) - High fasting blood glucose (FBG =100 mg/dL) - Recent skeletal muscle injury in less than one month before the start of the study - Use of antibiotics within 3 months prior to Visit 2 - Use of probiotics or supplements containing vitamins, minerals or antioxidants four weeks prior to Visit 2 - Regular smoking (including use of e-cigarettes) - Inability to correctly perform the PA test during screening/familiarization - Abuse of alcohol (alcohol consumption >20 units/week) and/or drugs - Plans to change diet or medication for the duration of the study - Treatment with an investigational drug (phase 1-3) 180 days before the start of the study - Inability to understand study information and/or communicate with staff

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Sweet orange and pomegranate extract
From the daily 650mg total supplementation of the investigational product, 250 mg will be of pomegranate extract containing 100mg of punicalagin. The remaining 400 mg will consist of sweet orange peel extract containing 360 mg of hesperidin.
Other:
Maltodextrin control
Supplementation with 760 mg maltodextrin

Locations

Country Name City State
Netherlands Maastricht University Maastricht

Sponsors (2)

Lead Sponsor Collaborator
Maastricht University BioActor B.V.

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in endurance capacity An Ekblom-bak cycling test is used to estimate the maximal oxygen consumption 12 weeks
Secondary Change in Daily physical activity Measured with an accelerometer 12 weeks
Secondary Change in Handgrip strength Measured with a dynamometer 12 weeks
Secondary Change in Self reported quality of life Measured with the World Health Organization Quality of Life (WHO-QOL-100) questionnaire. For 6 domains (including physical, psychological, level of independence, social relationships, environment and religion/personal beliefs), a score will be calculated between 2 - 40 in which a higher score indicates better quality of life. 12 weeks
Secondary Change in General health Measured with the 36-Item Short Form Health Survey. For 4 domains (including functional status, wellbeing, general health and change in health), a score will be calculated between 0 - 100 in which a higher score indicates better health. 12 weeks
Secondary Change in Vitality Measured with the vita-16 questionnaire. For 4 domains (including energy, motivation, resilience and overall vitality), a score will be calculated between 1 - 7 in which a higher score indicates higher vitality. 12 weeks
Secondary Change in Glucose levels Measured in blood samples 12 weeks
Secondary Change in Cholesterol levels Measured in blood samples 12 weeks
Secondary Change in Triglyceride levels Measured in blood samples 12 weeks
Secondary Change in Insulin levels Measured in blood samples 12 weeks
Secondary Change in Cortisol levels Measured in blood samples 12 weeks
Secondary Change in C-reactive protein levels Measured in blood samples 12 weeks
Secondary Change in Antioxidative capacity Measured with a TEAC assay in blood 12 weeks
Secondary Change in Cell elongation index Measured with immunohistochemistry in muscle tissue samples 12 weeks
Secondary Change in Muscle proliferation (marker Pax7) Measured with qPCR in muscle tissue samples 12 weeks
Secondary Change in Muscle differentiation (marker MyoD) Measured with qPCR in muscle tissue samples 12 weeks
Secondary Change in Muscle differentiation (marker Myogenin) Measured with qPCR in muscle tissue samples 12 weeks
Secondary Change in Muscle differentiation (marker Myosin Heavy Chain) Measured with qPCR in muscle tissue samples 12 weeks
Secondary Change in Muscle mitochondrial biogenesis (marker PGC1alpha) Measured with qPCR in muscle tissue samples 12 weeks
Secondary Change in Muscle metabolism (marker Glut4) Measured with qPCR in muscle tissue samples 12 weeks
Secondary Change in Muscle redox biology (marker GCLC) Measured with qPCR in muscle tissue samples 12 weeks
Secondary Change in Muscle redox biology (marker Hmox1) Measured with qPCR in muscle tissue samples 12 weeks
See also
  Status Clinical Trial Phase
Completed NCT01028599 - Effect of Physical Training on Oxygen Uptake and Endothelial Function in Heart Transplant Recipients N/A
Not yet recruiting NCT03940911 - Fatigue and Skeletal Muscle Impact in Severe Axial Spondyloarthritis N/A
Completed NCT04819282 - Mask Usage and Physical Performance During COVID-19 Pandemic in Geriatrics
Completed NCT04021342 - The Effect of Tart Cherry (Prunus Cerasus) Concentrate on Physiological and Cognitive Function N/A
Not yet recruiting NCT02575469 - Exercise Capacity in Diseases and Health N/A
Completed NCT01259739 - Cocoa Flavanols and Exercise Capacity N/A
Recruiting NCT00781807 - Rehabilitation and Outcome for Patients on LVAD Support N/A
Recruiting NCT04174664 - Comparison of Different Functional Capacity Tests in Cystic Fibrosis Patients With Acute Pulmonary Exacerbation
Recruiting NCT04611243 - Lung Function, Exercise Capacity, and Serology Responses in Patients With COVID-19
Completed NCT03531138 - Is it Possible to Use the Timed Performance Tests in Lung Transplantation Candidates to Determine the Exercise Capacity? N/A
Completed NCT04706650 - Exercise Capacity, Cardiovascular Risk Factors and Disease-related Variables in Axial Spondyloarthritis
Not yet recruiting NCT04241497 - Home-based Exercise Training in Patients With Pulmonary Arterial Hypertension: Effect on Skeletal Muscular Function and Metabolism N/A
Completed NCT06389734 - Combining Manual Soft Tissue Release and Exercise Training in COPD: the Effect on LF, EC, and CAF N/A
Completed NCT06014463 - Evaluation of Adult Patients With Immunodeficiency Within the Scope of the ICF
Recruiting NCT05416398 - Effects of High-intensity Interval Training and Aerobic Exercise on Obstructive Sleep Apnea. N/A
Active, not recruiting NCT01008306 - Cardiovascular Risk Factors After Renal Transplantation in Children and Adults N/A
Completed NCT00971594 - Age, Lifestyle, Muscle Mechanisms in Insulin Resistance N/A
Recruiting NCT05590169 - Effects of Telerehabilitation-based Exercises in Cystic Fibrosis N/A
Not yet recruiting NCT06018051 - "Can Do" Versus "Do Do" in Patients With Breast Cancer
Recruiting NCT05392920 - Determination of the Validity of One-Minute Sit-to-Stand Test in Obese and Overweight Children and Adolescents